Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD173 versus AD036 in obstructive sleep apnoea
ACTRN12619001427167Phase 2Completed
- Sponsor
- Flinders University
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of reboxetine + oxybutynin and atomoxetine + oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Flinders University. Primary endpoint: Sleep efficiency. Started Nov 2019; status: completed.
02
Drugs
reboxetine + oxybutyninatomoxetine + oxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ACTRN12619001427167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001427167.